Biomarker Assay Market Supply Demand 2016-2020
Research and development of biomarker discovery along with their clinical relevance is a new aspect for the pharmaceutical industry as compared to preclinical and pure research studies. Thus there is a very large latent scope for growth in this area. Technological advancements have provided excellent tools to all healthcare areas for analysis and development of biomarkers. Overall the biomarkers segment can be classified into several types namely, predisposition biomarkers, screening biomarkers, diagnostic biomarkers, predictive biomarkers, pharmacological biomarkers and prognostic biomarkers. Advanced proteomic and genomic analytical techniques have revealed a wide spectrum of mutations and their respective mutated proteins that are highly specific to various cancer types. Today biomarkers are helping medical professionals map out the likely course, stage and grade of various cancers.
Click For Full Report And Request TOC@ http://www.sa-brc.com/Global-Biomarker-Assay-Market-Assessment--Forecast-2016---2020/upcomingdetail33
In terms of applications, cancer biomarkers are available for various types such as lung, breast, prostate, liver, blood, colorectal, cervical, skin and pancreatic cancers. Several commercialized products in the market include BRAF mutation test, K-RAS mutation, EGFR + ALK test, BRCA, HER2, AFP, CA-19-9 & 125, CEA and others such as ROS-1, AKT and NRAS. The market for cancer biomarkers can also be segmented from the perspective of different geographies. This report intends to analyse the market for multiple regions of North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa. In terms of region, North America and Europe lead the market due to a very high rate of diagnoses in the regions. The developed regions also indicate the presence of niche specialty medical expertise in oncology that increases the diagnosis rates as compared to other regions of the world. Along with this, there is also a greater reach of good medical facilities in the developed regions such as United States, United Kingdom, France, Germany and Canada that adds to the prospects. This also represents an excellent opportunity for companies to acquire significant revenues from developing regions as there is a large fraction of cancer cases that go undiagnosed and unscreened for a long duration until the late stages.
The purpose of this report is to analyse the potential of screening and diagnoses of cancer in normal and at-risk people. This study is intended for manufacturers of assay kits, hospitals, medical experts, oncology experts, manufacturers of companion diagnostics and pharmaceutical companies among other avid readers who wish to understand this market. The report will benefit individuals understand the trends of the market in terms of targeted and personalized medicine and its progress. In 2014, the global cancer biomarkers market was estimated to be valued at US$ 8.0 billion and accounts for around 60% of the total biomarkers market. The cancer biomarkers market is expected to grow at a CAGR of 13% due to factors such as rising incidence of the top five cancer types that are breast, colorectal, lung, stomach and prostate. Key players in this area include Qiagen, Affymetrix, Illumina, Ambry Genetics, BioMerieux, Myriad Genetics, OriGene, Genomic Health, Molecular Response, Entrogen, Genoptix, Hoffman-La Roche and a plethora of other regional players.
For More Research Reports@ http://www.sa-brc.com/Medical-Devices/industry1
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.
10685-B Hazelhurst Drive,
Houston, Texas 77043,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biomarker Assay Market Supply Demand 2016-2020 here
News-ID: 400719 • Views: 342
More Releases from SA-BRC
Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The
More Releases for Genetic
Preimplantation Genetic Diagnosis: Scope & Revenue Outlook
Rising numbers of assisted reproductive procedures such as in vitro fertilization (IVF) is Asia is the most prominent factor driving the market for preimplantation genetic diagnosis. This is, in essence, the result of factors such as the delayed age of conception among Asian women, the rising rate of infertility among the population, and the significantly expanding medical tourism industry in the region. Rising disposable incomes and increased awareness regarding the
Preimplantation Genetic Testing Market-Size Report 2022
Preimplantation Genetic Testing Market by type 2017-2022 by new Service spreads across 204 pages profiling 17 companies and supported with 85 tables and 42 figures available at ReportsnReports.com Get sample copy for information professional insights@ http://www.reportsnreports.com/contacts/requestsample.aspx?name=1128201 “Preimplantation Genetic Testing Market projected to grow at a CAGR of 10.0%” The global preimplantation genetic testing market is expected to reach USD 541.8 million by 2022 from USD 336.4million in 2017, at a CAGR
India Genetic Testing Market Analysis
India is witnessing an accelerating shift towards the prevalence of non-communicable diseases, having secured third position in congenital malformations and genetic disorders as the commonest causes of mortality in neonates in cities. The ability to identify these non-communicable diseases at an early stage lies within the genetic screening segment. Genetic screening, however, is still in its infancy and there are many challenges that need to be overcome in order to
RBD Creative partners with Reproductive Genetic Innovations
Acknowledged in D Business' Faces of Detroit in 2015, RBD Creative, a local Plymouth marketing and design studio, is proud to announce a new partnership with Reproductive Genetic Innovations (RGI) of Northbrook, IL. RBD Creative specializes in health and wellness marketing solutions and has several notable clients including: University of Michigan Health System, University of Michigan School of Medicine, Lakes Urgent Care, Evangelical Homes of Michigan, Cryowellness USA, Michigan Reproductive
Preimplantation Genetic Diagnosis - Saving Offsprings From Any Genetic Disorder
The market for preimplantation genetic diagnosis (PGD) in Asia features high fragmentation when it comes to diagnostic service providers. The large number of local players has intensified the competitive rivalry in the region. However, owing to the lack of better alternatives to PGD, costs of these procedures remain high, a major limiting factor for the market, especially in cost-sensitive developing countries in the region. A recent report by TMR suggests that
OGT aids research into molecular genetic disease
Unique CytoSure™ Molecular Testing Arrays provide high throughput CNV detection for multiple disorders on a single chip Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a new range of CytoSure™ Molecular Testing Arrays and Panels. The new DNA microarrays utilise a unique collection of probes for detecting copy number variations (CNVs) within genes associated with a variety of disorders. Three